News

Targeted Oncology11d
Treatment Approaches for Non–Transplant Eligible Patients With BPDCN
An expert discusses how effective blastic plasmacytoid dendritic cell neoplasm (BPDCN) management requires early central ...
Targeted Oncology11d
Tagraxofusp: CD123-Targeted Therapy for Frontline Treatment of BPDCN
An expert discusses how treatment selection in blastic plasmacytoid dendritic cell neoplasm (BPDCN) involves balancing ...
EurekAlert!5d
Integrating in situ vaccination with checkpoint blockade therapy: a novel approach to enhance anti-tumor immunity in colorectal cancer
This paper also discussed the use of Dendritic cells (DCs) for the In Situ Vaccination (ISV) treatment approach. ISV is a technique that utilises tumour antigens present at the site of the tumour ...
Renal Cell Carcinoma Pipeline Appears Robust With 30+ Companies Actively Working in the Therapeutics Segment | DelveInsight
DelveInsight’s Renal Cell Carcinoma Pipeline report depicts a robust space with 30+ active players working to develop 30+ ...
NetNewsLedger7d
Pancreatic Cancer Care in Germany: What You Need to Know
Pancreatic cancer remains one of the most formidable oncological challenges of our time. Known for its late detection and ...
Technology Networks13d
Researchers Uncover a Way To Boost Treatment for Aggressive Melanoma
A new study from researchers at Moffitt Cancer Center shows that blocking a chemical process called nitrosylation could make ...
Cutaneous Lupus Erythematosus Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies
In April 2025, Pfizer organized a study is to learn about the effects, safety and how PF-06823859 is processed in adults with ...